BTRX 246040

Drug Profile

BTRX 246040

Alternative Names: BTRX-246040; LY 2940094

Latest Information Update: 10 Jun 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer BlackThorn Therapeutics; Eli Lilly
  • Class Antidepressants; Small molecules
  • Mechanism of Action Nociceptin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neurological disorders
  • Discontinued Alcoholism; Major depressive disorder

Most Recent Events

  • 07 Jun 2017 BlackThorn Therapeutics collaborates with Mindstrong Health to use the patented and validated technology for the clinical studies of BTRX 246040
  • 07 Jun 2017 BlackThorn Therapeutics plans a series of phase IIa trials of BTRX 246040 for Neurological disorders in the second half of 2017
  • 20 Oct 2016 Phase-II clinical trials in Neurological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top